CN101437491B - 用于免疫疗法的纳米颗粒 - Google Patents

用于免疫疗法的纳米颗粒 Download PDF

Info

Publication number
CN101437491B
CN101437491B CN2007800143677A CN200780014367A CN101437491B CN 101437491 B CN101437491 B CN 101437491B CN 2007800143677 A CN2007800143677 A CN 2007800143677A CN 200780014367 A CN200780014367 A CN 200780014367A CN 101437491 B CN101437491 B CN 101437491B
Authority
CN
China
Prior art keywords
nanoparticles
polymer
compositions
antigen
pluronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800143677A
Other languages
English (en)
Chinese (zh)
Other versions
CN101437491A (zh
Inventor
赛·T·雷迪
杰弗里·A·哈贝尔
梅洛迪·A·斯沃茨
安德烈·范德弗利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ECOLE POLYTECH
Original Assignee
ECOLE POLYTECH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ECOLE POLYTECH filed Critical ECOLE POLYTECH
Publication of CN101437491A publication Critical patent/CN101437491A/zh
Application granted granted Critical
Publication of CN101437491B publication Critical patent/CN101437491B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800143677A 2006-02-21 2007-02-21 用于免疫疗法的纳米颗粒 Active CN101437491B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77513206P 2006-02-21 2006-02-21
US60/775,132 2006-02-21
US11/707,627 2007-02-19
US11/707,627 US8021689B2 (en) 2006-02-21 2007-02-19 Nanoparticles for immunotherapy
PCT/US2007/004671 WO2007098254A2 (en) 2006-02-21 2007-02-21 Nanoparticles for immunotherapy

Publications (2)

Publication Number Publication Date
CN101437491A CN101437491A (zh) 2009-05-20
CN101437491B true CN101437491B (zh) 2013-01-02

Family

ID=38438002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800143677A Active CN101437491B (zh) 2006-02-21 2007-02-21 用于免疫疗法的纳米颗粒

Country Status (8)

Country Link
US (1) US8021689B2 (https=)
EP (1) EP1993511B1 (https=)
JP (1) JP5506196B2 (https=)
CN (1) CN101437491B (https=)
AU (1) AU2007217514B2 (https=)
CA (1) CA2661700C (https=)
ES (1) ES2709391T3 (https=)
WO (1) WO2007098254A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
JP2011500569A (ja) * 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US8323696B2 (en) * 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US9271929B2 (en) * 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
CA2798739A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2013121296A1 (en) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
DE102010040565A1 (de) 2010-09-10 2012-03-15 Robert Bosch Gmbh Verfahren zum Einstellen der von einer Feststellbremse ausgeübten Klemmkraft
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
MX374963B (es) * 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US9540428B2 (en) 2012-07-03 2017-01-10 Ecole Polytechnique Federale De Lausanne (Epfl) Extracellular matrix heparin-binding domains
US9879062B2 (en) 2012-07-03 2018-01-30 Ecole Polytechnique Federale De Lausanne Protein-binding peptide isolated from placenta growth factor
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
EP3092283B1 (en) 2014-01-06 2020-07-22 Nanoco Technologies Ltd Surface-modified nanoparticles
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US20150359865A1 (en) * 2014-06-17 2015-12-17 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US20180280488A1 (en) * 2017-03-31 2018-10-04 University of Alaska Anchorage Methods and Compositions for Binding Complement C3 for Targeting of Immune Cells
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
US11732029B2 (en) 2017-11-13 2023-08-22 The University Chicago Methods and compositions for the treatment of wounds
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
GB201918963D0 (en) * 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants
CN114053433B (zh) * 2021-10-20 2024-10-18 北京中医药大学东方医院 刺激响应型纳米材料及其在制备原位肿瘤疫苗中的用途
CN114259463B (zh) * 2022-02-11 2023-03-28 山东大学 一种靶向补体蛋白发挥抗炎作用的PF-HA-diSE水凝胶及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2167920A1 (en) * 1993-07-23 1995-02-02 Abraham J. Domb Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
EP0954222A4 (en) 1996-04-10 2003-01-15 Univ Southern California GENE THERAPY FOR PROLIFERATIVE VITREORETINOPATHY
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
GB9718129D0 (en) 1997-08-27 1997-10-29 Isis Innovation Branched structures
TWI221854B (en) 2000-05-26 2004-10-11 Anawrahta Biotech Co Ltd Lac shuttle vectors, kit for expression of a heterologous gene and DNA vaccine carrier containing the same
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
EP1515981A4 (en) 2001-01-31 2005-03-23 Millennium Pharm Inc NEW MOLECULES OF THE PYRINE / NBS / LRR PROTEIN FAMILY AND ITS USES
MXPA03007665A (es) 2001-02-26 2004-03-16 Univ Duke Polimeros dendriticos novedosos y sus usos biomedicos.
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US7316816B2 (en) * 2004-06-10 2008-01-08 Agency For Science Technology And Research Temperature and pH sensitive copolymers
US20060204443A1 (en) 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility

Also Published As

Publication number Publication date
WO2007098254A3 (en) 2008-09-25
EP1993511A4 (en) 2014-11-05
EP1993511B1 (en) 2018-10-31
CN101437491A (zh) 2009-05-20
EP1993511A2 (en) 2008-11-26
JP2009527566A (ja) 2009-07-30
ES2709391T3 (es) 2019-04-16
US20080031899A1 (en) 2008-02-07
AU2007217514A1 (en) 2007-08-30
WO2007098254A2 (en) 2007-08-30
CA2661700A1 (en) 2007-08-30
AU2007217514B2 (en) 2013-02-21
CA2661700C (en) 2020-07-07
JP5506196B2 (ja) 2014-05-28
US8021689B2 (en) 2011-09-20

Similar Documents

Publication Publication Date Title
CN101437491B (zh) 用于免疫疗法的纳米颗粒
CN102202653B (zh) 用于免疫疗法的纳米颗粒
Wagner et al. Mesoporous silica nanoparticles as pH-responsive carrier for the immune-activating drug resiquimod enhance the local immune response in mice
JP7586863B2 (ja) 共有ポリマー抗原コンジュゲート化粒子
US20220143160A1 (en) Compositions Comprising Apoptotic Signaling and Methods for Induction of Antigen-Specific Tolerance
Reddy et al. In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles
JP2025163048A (ja) ペプチドコンジュゲート粒子
JP2025069142A (ja) スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
HK1131551A (en) Nanoparticles for immunotherapy
Ruff Particle-based vaccination through direct targeting of antigen presenting cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131551

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1131551

Country of ref document: HK